You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Oncol., 27 November 2023

Sec. Pediatric Oncology

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1333273

Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients

    EM

    Ema Mosleh 1*

    SS

    Stacy Snyder 1

    NW

    Ningying Wu 2

    DN

    Daniel N. Willis 1

    RM

    Rema Malone 3

    RJ

    Robert J. Hayashi 1

  • 1. Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States

  • 2. Biostatistics Shared Resource, Division of Public Health Sciences and Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States

  • 3. Division of Pediatric Hematology/Oncology, St. Louis Children’s Hospital, St. Louis, MO, United States

Article metrics

View details

1

Citations

966

Views

443

Downloads

In the original article, there was an error in the author list order, as published. Instead of “Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Robert J. Hayashi1, Rema Malone3”, It should be “Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Rema Malone3, Robert J. Hayashi1”.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

methotrexate, HDMTX, supportive care, delayed clearance, nephrotoxicity, adverse effect, pediatric cancer, AYA

Citation

Mosleh E, Snyder S, Wu N, Willis DN, Malone R and Hayashi RJ (2023) Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients. Front. Oncol. 13:1333273. doi: 10.3389/fonc.2023.1333273

Received

04 November 2023

Accepted

08 November 2023

Published

27 November 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2023

Updates

Copyright

*Correspondence: Ema Mosleh,

†Present address: Stacy Snyder, Beacon Health System, South Bend, IN, United States

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics